Christopher Peetz has served as a member of our board of directors since April 2018. Mr. Peetz serves as the CEO of Flashlight Therapeutics, Inc. and has been an Entrepreneur-in-Residence at Frazier Healthcare Partners since May 2017. He served as Chief Financial Officer and Head of Corporate Development at Tobira Therapeutics, Inc., a biotechnology company acquired by Allergan plc in November 2016, from May 2014 to December 2016. Prior to joining Tobira Therapeutics, Mr. Peetz served as Vice President, Finance & Corporate Development of Jennerex Biotherapeutics, a privately held biopharmaceutical company. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc. (now Amgen), including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.